2017 - Pharma Rep Focus

Merck settles with insurance companies over $1.4B claim tied to 2017 cyberattack: report

Fierce Pharma

JANUARY 4, 2024

billion claim after it was victimized by a crippling cyberattack in 2017. billion claim after it was victimized by a crippling cyberattack in 2017, Bloomberg Law reports. Merck has reportedly settled with insurance companies that contested the pharma giant’s $1.4

Insurance

Insurance Pharma

PTC wins FDA approval for first brain-delivered gene therapy Kebilidi

Fierce Pharma

NOVEMBER 14, 2024

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.

FDA

Steep drop for UK industry clinical trials between 2017 and 2021

European Pharmaceutical Review

OCTOBER 24, 2022

The number of industry clinical trials initiated in the UK, per year, fell by 41 percent from 2017 to 2021, according to the latest annual report on clinical research from the Association of the British Pharmaceutical Industry ( ABPI ). million people living with rare diseases in the UK.

Recruitment

Recruitment Pharmaceutical Patients Government

Webinars

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

MORE WEBINARS

With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer

Fierce Pharma

FEBRUARY 13, 2024

It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer.

FDA

FDA Patients

Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus

Fierce Pharma

SEPTEMBER 13, 2024

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | The day after Roche gained an FDA approval for its subcutaneous version of cancer drug Tecentriq, the company also scored with a U.S. nod for its under-the-skin formulation of mega-blockbuster multiple sclerosis drug Ocrevus.

FDA

FDA Patients

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

Fierce Pharma

MARCH 20, 2024

After Johnson & Johnson last year changed its mind on its 2017 purchase of ap | Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said.

FDA

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Fierce Pharma

APRIL 8, 2024

Many cancer meds approved under the FDA's accelerated approval pathway from 2013 to 2017 didn't improve overall survival after more than five years of follow-up research, the study found. One hallmark of the FDA's accelerated approval pathway is the requirement that medicines prove their benefits in confirmatory trials.

FDA

FDA Medicine

Sanofi stands behind 'accuracy of our accounts' amid reports of French manipulation probe

Fierce Pharma

NOVEMBER 7, 2023

Since launching the Regeneron-partnered antibody Dupixent in 2017, Sanofi has relied on the star medicine for sales growth.

Medicine

Medicine Sales

Merck, insurers advance fight over cyberattack-related coverage to New Jersey Supreme Court

Fierce Pharma

JULY 27, 2023

scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. scored a legal win in the insurance case tied to the 2017 "NotPetya" cyberattack, the case is in appeals—again. About a month and a half after Merck & Co. That didn't take long.

Insurance

Samsung Biologics upgrades another production pact, this time with Baxter for $223M

Fierce Pharma

JUNE 20, 2024

The revised deal, first established back in July of 2017, will now see Baxter pay Samsung upwards of $223 million for its manufacturing services through end of 2034. On a revised dealmaking spree this year, Korea’s Samsung Biologics is re-tooling its long-running drug manufacturing pact with Baxter Healthcare. |

Manufacturing

Manufacturing Healthcare Healthcare

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

Fierce Pharma

DECEMBER 6, 2023

In 2017, Daiichi's former subsidiary Plexxikon alleged that Novartis stepped on its Zelboraf patents with its GSK-acquired medicine Tafinlar. After years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. |

Medicine

Preserving Patient Access to Compounded Medications Act of 2017

Pharmacy Times

SEPTEMBER 14, 2023

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

Medical

Medical Patients

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

Fierce Pharma

AUGUST 22, 2023

Ingrezza was first approved in tardive dyskinesia in 2017. With a new FDA approval to rival Teva's Austedo, Neurocrine Biosciences’ Ingrezza is debuting in a treatment area with hundreds of millions of dollars of revenue potential. | The FDA approved Ingrezza capsules to treat adult with chorea associated with Huntington’s disease.

FDA

FDA Pharmaceutical

Former Novartis execs cleared of Greek bribery charges after yearslong investigation

Fierce Pharma

MAY 31, 2023

After an investigation that dates back to 2017, four former Novartis executives and a Greek politician were cleared of bribery charges. After a yearslong investigation involving politicians and medical professionals alike, Novartis is looking to close the books on its Greek bribery imbroglio.

Doctors

Doctors Medical

Sanofi shakes up leadership as specialty care head Sibold departs to pursue outside opportunity

Fierce Pharma

AUGUST 31, 2023

Bill Sibold, who took over the company's specialty care unit in 2017 just after Dupixent's first approval, is leaving Sanofi effective immediately. For six years, Sanofi's specialty care chief Bill Sibold has helped the company make the most of its Regeneron-partnered immunology superstar Dupixent.

Lilly forks over $2.4M to settle federal agency's age discrimination lawsuit

Fierce Pharma

JUNE 27, 2023

Equal Employment Opportunity Commission, which sued the company in September over claims it had changed its hiring preferences in 2017 to prioritize recruitment of more millennials to its workforce. . | Eli Lilly will pay out $2.4 million as part of a settlement agreement with the U.S.

Recruitment

Apotex, Heritage and Breckenridge settle with purchasers in generics price-fixing case

Fierce Pharma

JANUARY 24, 2024

Apotex and two of its generics peers have agreed to settle with direct purchasers of their drugs in a price-fixing case that stretches all the way back to 2017. Over the years, myriad generic drugmakers have had to ante up fines and settlement fees for allegedly colluding on the prices of copycat drugs.

FDA approves Pfizer spinout SpringWorks' Ogsiveo as first treatment for disfiguring rare tumor type

Fierce Pharma

NOVEMBER 20, 2023

Patients with ultra-rare desmoid tumors now have an FDA-approved treatment, thanks to a drug made by SpringWorks Therapeutics, which spun out of Pfizer in 2017 with a portfolio of rare disease candidates. Thanks to a new FDA approval, patients with ultra-rare desmoid tumors now have an FDA-approved treatment.

FDA

FDA Patients

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Fierce Pharma

JULY 5, 2023

Since 2017, the company has sold off three PRVs—getting less in return for each successive sale. While the price of just about everything has increased over the last six years in the U.S., the same can’t be said for the cost of an FDA priority review voucher. Just ask Sarepta Therapeutics. | The price of priority review vouchers is falling.

FDA

FDA Sales

Fierce Pharma Asia—BioNTech's ADC clinical hold; Takeda's leukemia bet; China NMPA's meeting with FDA

Fierce Pharma

JUNE 20, 2024

drug authorities met at the FDA's headquarters for the first time since 2017. Takeda has identified a potential challenger to Novartis' Scemblix. Senior officials from China and U.S. And more.

FDA

FDA Pharma

The 10 Blog Posts Sales Leaders Found Most Helpful in 2017

The Brooks Group

DECEMBER 4, 2017

We’ve rounded up the top 10 most popular posts from The Sales Leader blog in 2017 to give you a place to start when you’re looking to improve your team’s performance. Top 10 Sales Effectiveness Articles from 2017. 4 Step Action Plan for Sales Target Achievement.

Sales

Sales Prospecting Sales Management Sales territory

Study points to weaknesses in FDA accelerated approval path

pharmaphorum

APRIL 8, 2024

Less than half of the cancer therapies given accelerated approval by the FDA in 2013 to 2017 showed a clinical benefit in a confirmatory trial within the next five years

FDA

Evernorth: 1 in 4 Adults Diagnosed with ADHD Don’t Get Treated

MedCity News

JUNE 28, 2023

in 2017. An Evernorth study found that in 2021, 25% of adults with ADHD did not receive any treatment, though this is a decrease from 38.5% About 21.4% of adults with ADHD received both medication and behavioral therapy in 2021, up from 12.9%

Medical

2017 in Review – Birthdays, Gong Ringing, and the Future of Sales Training

The Brooks Group

DECEMBER 27, 2017

2017 was a big year for The Brooks Group. 2017 was the year of the sales training revolution, with the world-renowned IMPACT Selling being released in an eLearning platform, IMPACT-U® ! 2017 heard quite a few gong rings! The entire team at The Brooks Group is feeling motivated and charged up after such a strong 2017.

Training

Training Sales Sales goal Consulting

Radiopharmaceuticals reach record high with $408m in venture financing for 2023

Pharmaceutical Technology

NOVEMBER 28, 2023

Venture financing for innovative radiopharmaceutical drugs witnessed an approximately 550% increase from $63m in 2017 to $408m in 2023 YTD (year-to-date) total deal value in the US.

CustomersFirst Now Announces New Release of CFN Insight™ at the Gainsight Pulse 2017 Customer Success Conference

Clarivate

MAY 10, 2017

Look for the CustomersFirst Now booth at Pulse 2017 on May 9-11 at the Oakland Convention Center to see the latest features in CFN Insight , or to get an in-person demo to see how we can accelerate your Customer Success implementation. OAKLAND, Calif. For more information, or to get a free trial or demo, please visit [link] cfn-insight/.

Media

Media Management Leads Training

Validating Pharma 4.0 for Smart Manufacturing

PharmaTech

SEPTEMBER 18, 2024

a term coined in 2017 by the International Society for Pharmaceutical Engineers, promises a revolution across drug discovery, manufacturing, and supply chain logistics, ensuring drugs are delivered precisely when needed, and improving overall patient care. The drug manufacturing ecosystem Pharma 4.0,

Manufacturing

Manufacturing Pharma Engineering Pharmaceutical

CVS scheme diverted millions from underserved population, NY AG says

MedCity News

JULY 28, 2022

Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program.

Prescription

Prescription Safety

Biden proposes subsidizing drug middlemen for insulin

World of DTC Marketing

MARCH 31, 2022

Between 2017 and 2019, pharmacy benefit managers’ gross profit increased by 12 percent despite PBM retention of manufacturer rebates decreasing during this period, according to a report released on Dec. The report showed that the PBM gross profit increased from $25 billion to $28 billion between 2017 and 2019.

Insurance

Insurance Prescription Manufacturing Sales

The race for a new class of antibiotics

European Pharmaceutical Review

NOVEMBER 21, 2022

A study on the surge of new antimicrobial research has shown that despite almost a quarter of a million research papers (227,808) being published on the 12 bacterial families in the World Health Organization (WHO) global priority pathogen list of antibiotic-resistant bacteria from 2017, no new class of antibiotics has gone to market since 1987.

Management

Management Leads Pharmaceutical Marketing

Report: More Traditional Medicare Enrollees Are Buying Medicare Supplement Coverage

MedCity News

APRIL 10, 2023

The share of traditional Medicare enrollees who bought Medicare Supplement coverage rose to 41% in 2021, compared to 35% in 2017, according to a report from America’s Health Insurance Plans. Medicare Supplement enrollees are three times less likely to have issues paying medical bills than those who only have traditional Medicare.

Insurance

Insurance Medical

Lung cancer deaths decline but.

World of DTC Marketing

FEBRUARY 17, 2022

In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017. In recent years, early detection and treatment improvements have helped boost the 3-year survival rate for lung cancer from 21% in 2004 to 31% in 2015 through 2017.

Medicine

Medicine Insurance Leads Medical

W. Va. judge sides with drug distributors in bellwether opioid trial

MedCity News

JULY 7, 2022

From 2001 to 2017, the fatal overdose rate in Cabell County increased from 16.6 per 100,000. Judge finds no evidence of causation.

Biopharma

Biopharma Healthcare Healthcare

Among Employers Offering Retiree Health Benefits, More Are Turning to MA Plans

MedCity News

DECEMBER 5, 2022

Of this group, 50% provide these benefits through a Medicare Advantage plan, up from 26% in 2017. Currently, only 13% of large employers — or companies with 200 or more employees — offer retiree health benefits, the Kaiser Family Foundation survey found.

FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease

Pharmacy Times

JULY 24, 2024

In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.

FDA

FDA Patients

Ukrainian research contributions to the UN Sustainable Development Goals

Clarivate

APRIL 14, 2022

Our research shows that Ukraine has contributed more than 5,000 scientific publications towards the UN Sustainable Development Goals since 2017, including on peace and justice initiatives (SDG-16). According to our data, Ukraine contributed a total of 5,863 scientific publications towards SDGs since 2017 (see figure 2).

Government

Government Education Distribution Food

Clarivate announces the inaugural Eugene Garfield Memorial Lecture

Clarivate

SEPTEMBER 18, 2023

As a pioneer in automated indexing and retrieval of information since 1955, Eugene Garfield (1925-2017) developed citation databases for science that changed how researchers search and assess the scholarly literature.

Specialization

Specialization Networking Leads Professional Services

Pivotal bioVenture raises the stakes in biotech and pharmaceutical support

Pharmaceutical Technology

DECEMBER 18, 2023

The latest $389m pledge follows an initial investment of $300m in 2017 that was raised to fund early-stage life-science startups.

Pharmaceutical

Takeda ends microbiome alliance with Finch Therapeutics after pipeline review

MedCity News

AUGUST 28, 2022

The biotech company had been collaborating with Takeda Pharmaceutical since 2017. The agreement termination means that two preclinical microbiome therapy candidates for inflammatory bowel disease will now return to Finch Therapeutics.

Pharmaceutical

Pharmaceutical Biopharma Pharma

ADCs dominate with billion-dollar licensing agreements in 2022

Pharmaceutical Technology

OCTOBER 5, 2023

Antibody-drug conjugates (ADCs) saw a 400% growth in total licensing agreement deal value from 2017 to 2022 and reached a peak of $16.6bn.

Ukraine: Innovation, technology and cutting-edge research

Clarivate

APRIL 21, 2022

As can be seen from Figure 1, between 2017-2021, Ukraine’s research output focused on macro topics such as physics (19%), clinical and life sciences (16%), chemistry (16%), social sciences (12%), engineering and material sciences (10%), and electrical engineering (10%) with a total of 52,618 papers published. Source: InCites.

Engineering

Engineering Education Electronics Medicine

FDA Expands Indication of Pfizer's Besponsa to Include Pediatric Patients with B-cell Precursor Acute Lymphoblastic Leukemia

PharmExec

MARCH 7, 2024

Besponsa (inotuzumab ozogamicin) was initially approved in August 2017 for adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.

Patients

Patients FDA

TriLink Biotechnologies Introduces CleanCap M6 Analog

PharmaTech

MAY 16, 2023

The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.

Survey reports on falsification of medical devices

European Pharmaceutical Review

DECEMBER 1, 2023

Additionally, given implementation of the latest EU regulations applicable to medical devices (2017/745 and 2017/746) is “still in its early stages”, there is little information on the impact of these regulations in addressing the falsified medical devices.

Medical

Medical Pharmaceutical

Merck settles with insurance companies over $1.4B claim tied to 2017 cyberattack: report

PTC wins FDA approval for first brain-delivered gene therapy Kebilidi

Webinars

Trending Sources

Steep drop for UK industry clinical trials between 2017 and 2021

Webinars

With FDA nod for Onivyde combo, Ipsen ends 10-year drought in newly diagnosed pancreatic cancer

Roche doubles down with another subcutaneous FDA nod, this one for MS star Ocrevus

Idorsia's Tryvio crosses FDA finish line, offering new mechanism to treat hypertension

'Most' cancer meds approved under FDA's accelerated pathway couldn't prove survival benefit after 5 years: study

Sanofi stands behind 'accuracy of our accounts' amid reports of French manipulation probe

Merck, insurers advance fight over cyberattack-related coverage to New Jersey Supreme Court

Samsung Biologics upgrades another production pact, this time with Baxter for $223M

Daiichi Sankyo scores $182M from Novartis settlement in long-running patent case

Preserving Patient Access to Compounded Medications Act of 2017

Look out, Teva. Neurocrine's Ingrezza wins Huntington's disease FDA nod to rival Austedo

Former Novartis execs cleared of Greek bribery charges after yearslong investigation

Sanofi shakes up leadership as specialty care head Sibold departs to pursue outside opportunity

Lilly forks over $2.4M to settle federal agency's age discrimination lawsuit

Apotex, Heritage and Breckenridge settle with purchasers in generics price-fixing case

FDA approves Pfizer spinout SpringWorks' Ogsiveo as first treatment for disfiguring rare tumor type

Sarepta sells FDA priority review voucher to mystery buyer for $102M as prices continue to slip

Fierce Pharma Asia—BioNTech's ADC clinical hold; Takeda's leukemia bet; China NMPA's meeting with FDA

The 10 Blog Posts Sales Leaders Found Most Helpful in 2017

Study points to weaknesses in FDA accelerated approval path

Evernorth: 1 in 4 Adults Diagnosed with ADHD Don’t Get Treated

2017 in Review – Birthdays, Gong Ringing, and the Future of Sales Training

Radiopharmaceuticals reach record high with $408m in venture financing for 2023

CustomersFirst Now Announces New Release of CFN Insight™ at the Gainsight Pulse 2017 Customer Success Conference

Validating Pharma 4.0 for Smart Manufacturing

CVS scheme diverted millions from underserved population, NY AG says

Biden proposes subsidizing drug middlemen for insulin

The race for a new class of antibiotics

Report: More Traditional Medicare Enrollees Are Buying Medicare Supplement Coverage

Lung cancer deaths decline but.

W. Va. judge sides with drug distributors in bellwether opioid trial

Among Employers Offering Retiree Health Benefits, More Are Turning to MA Plans

FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease

Ukrainian research contributions to the UN Sustainable Development Goals

Clarivate announces the inaugural Eugene Garfield Memorial Lecture

Pivotal bioVenture raises the stakes in biotech and pharmaceutical support

Takeda ends microbiome alliance with Finch Therapeutics after pipeline review

ADCs dominate with billion-dollar licensing agreements in 2022

Ukraine: Innovation, technology and cutting-edge research

FDA Expands Indication of Pfizer's Besponsa to Include Pediatric Patients with B-cell Precursor Acute Lymphoblastic Leukemia

TriLink Biotechnologies Introduces CleanCap M6 Analog

Survey reports on falsification of medical devices

Stay Connected